Dr. Isufi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
20 York Street
Yale New Haven Hospital
New Haven, CT 06510Phone+1 203-200-4363Fax+1 203-200-2026- Is this information wrong?
Education & Training
- Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
- Stony Brook University Health Sciences Center School of MedicineClass of 2004
Certifications & Licensure
- CT State Medical License 2011 - 2025
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Start of enrollment: 2016 Oct 01
- Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Start of enrollment: 2019 Apr 16
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2018 Mar 06
Roles: Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.Madiha Iqbal, Deepa Jagadeesh, Julio Chavez, Arushi Khurana, Allison Rosenthal, Emily Craver, Narendranath Epperla, Zhuo Li, Iris Isufi, Farrukh T Awan, Bhagirathbhai ...> ;Bone Marrow Transplantation. 2024 Feb 1
- A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.Reid W Merryman, Robert A Redd, Arnold S Freedman, Inhye E Ahn, Jennifer R Brown, Jennifer L Crombie, Matthew S Davids, David C Fisher, Eric D Jacobsen, Austin I Kim, ...> ;Annals of Hematology. 2024 Jan 1
- 9 citationsCost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma.Mengyang Di, Iris Isufi, Lohith Gowda, Stuart E Seropian, Francine M Foss, Howard P Forman, Scott F Huntington, Potnis, K.> ;Blood Advances. 2023 Mar 14
- Join now to see all
Abstracts/Posters
- A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...Iris Isufi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell TransplantationIris Isufi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell LymphomaIris Isufi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
- Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022
Professional Memberships
- Member
Hospital Affiliations
- Yale-New Haven HospitalNew Haven, Connecticut
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: